Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lomecel-B in Alzheimer's Disease
NCT02600130Phase 1Completed
- Sponsor
- Longeveron
- Start
- Oct 2016
- Primary completion
- Sep 2020
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of laromestrocel in Alzheimer's disease (AD) (3 arms), sponsored by Longeveron. Primary endpoint: Safety of LMSCs administered to subjects with Alzheimer's disease at 30 days. Started Oct 2016; status: completed.
02
Drugs
laromestrocel
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02600130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02600130.